Compare VIRT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIRT | BEAM |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.7B |
| IPO Year | 2014 | 2019 |
| Metric | VIRT | BEAM |
|---|---|---|
| Price | $42.85 | $25.30 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $43.71 | ★ $51.00 |
| AVG Volume (30 Days) | 928.1K | ★ 1.7M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | 72.73 | ★ 82.31 |
| EPS | ★ 5.13 | N/A |
| Revenue | ★ $3,632,118,000.00 | $24,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.41 | $39.64 |
| P/E Ratio | $8.12 | ★ N/A |
| Revenue Growth | 26.25 | ★ 33.33 |
| 52 Week Low | $31.55 | $13.53 |
| 52 Week High | $45.77 | $36.44 |
| Indicator | VIRT | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 64.30 | 44.10 |
| Support Level | $42.53 | $23.42 |
| Resistance Level | $42.90 | $25.69 |
| Average True Range (ATR) | 1.21 | 1.29 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 96.33 | 23.31 |
Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.